Overview

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a combination of drugs considered standard treatment for children and young adults with acute lymphoblastic leukemia (ALL), in combination with a new drug called MLN 9708. Additionally, the study is also evaluating if bone marrow or stem cell transplantation, which will be given to some participants, helps to prevent ALL from returning.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Millennium Pharmaceuticals, Inc.
Treatments:
6-Mercaptopurine
Cyclophosphamide
Cytarabine
Doxorubicin
Glycine
Ixazomib
Liposomal doxorubicin
Mercaptopurine
Methotrexate
Vincristine